Variability in Human Fatty Acids Profiles Based on Blood Fractions and Metabolic Conditions

In summary, it is known that numerous factors can interfere with the effects of administering polyunsaturated fatty acids (n-3 PUFA), including aspects related to the experimental design, such as the form and dosage used, the duration of treatments, the blood fraction and the metabolic state of the individuals. In this context, given the importance of precise quantification of fatty acids in biological samples obtained from humans, the present study will aim to evaluate the variability caused by the administration of fish oil before and after 8 weeks of supplementation. This will involve comparing the fatty acid profiles according to different fractions (plasma, leukocytes, and erythrocytes) and fasting conditions (fasting or post-prandial). In plasma, the analysis will also consider both the total sample and the phospholipidic fraction.

Inclusion criteria

• Individuals of both sexes
• Aged between 20 and 50 years
• No contraindications for the use of fish oil supplements

Exclusion criteria

• Use of medications or supplements to reduce triacylglycerols;
• Consumption of fish oil or other supplements/medicines rich in n-3 or n-6 PUFA in the month before the test;
• Consumption of fatty fish (salmon, herring, mackerel, white tuna or sardines) more than twice a month in the month before the test;
• Refusal to avoid PUFA supplements and seafood during the study period;
• Severe heart failure;
• Severe active liver disease;
• Planned coronary intervention or surgery,
• History of acute or chronic pancreatitis;
• Hypersensitivity to fish, shellfish or capsule ingredients;
• Autoimmune diseases requiring immunosuppressive therapy;
• Current corticosteroid use systemic,
• Neoplasms;
• Chemotherapy or radiotherapy within the past 12 months (patients who have undergone curative surgery without requiring additional treatment within the past year may be included);
• Inflammatory bowel disease;
• Chronic diarrhea;
• Significant non-transient hematological abnormalities;
• Kidney dysfunction;
• Severe liver disease;
• Inability to provide informed record;
• Participation in another clinical trial with an experimental agent in the last 90 days;
• Malabsorption syndrome;
• Recent drug or alcohol abuse;
• Atrial fibrillation;
• Bleeding disorders.
• Pregnancy
• Breastfeeding.